BGM0504 for type 2 diabetes in Indonesia
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new medicine called BGM0504 for people with type 2 diabetes who are already taking metformin. It may help improve blood sugar control and weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes.
- You are taking metformin (a standard diabetes pill) at a dose of at least 1000 mg per day for at least 8 weeks.
- Your body mass index (BMI) is 23 or higher.
- Your weight has been stable (within 5%) for the past 3 months.
- Your HbA1c (average blood sugar over 2-3 months) is between 7.5% and 11.0%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, BGM0504, for people recently diagnosed with type 2 diabetes who also have obesity. It aims to see if the drug can help control blood sugar and support weight loss.
This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.
This trial tests an investigational drug called BGM0504 in people with type 2 diabetes who are already taking metformin or metformin plus another diabetes medicine. It aims to see if the drug can help lower blood sugar levels.
This trial tests a new medication called BGM0504 for people with type 2 diabetes that is not well managed with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels.
This study tests a new medication called bofanglutide in adults with type 2 diabetes who are currently taking metformin. The medication works similarly to a hormone that helps control blood sugar, and the study aims to see if it can help lower blood sugar levels and manage weight better.
This trial tests a new medication called PG-102 for people with type 2 diabetes. It compares PG-102 to a placebo (inactive treatment) and semaglutide (a standard diabetes drug) to see if it can help lower blood sugar and potentially help with weight loss.
Hear when a new Type 2 Diabetes (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.